BioPorto A/S BIOPOR
OMXCOP · Denmark · Health Technology
DKK 1.05-0.01 (-1.41%)
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
September 28, 2026News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company's future.At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cash flow
September 24, 2026News release Reminder: Register Now | Unlocking the Growth - BioPorto Investor Meeting, October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, we invite you to join us for an afternoon focused on the key drivers that may shape the Company's future.At the event, management will provide an update on BioPorto's commercial progress, regulatory initiatives, strategic priorities, and path toward sustainable growth and cas
September 16, 2026News Release First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study. COPENHAGEN, DENMARK, September 16 , 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced the enrollment of the first patient as part of the ProNephro AKI U.S. Adult Urine NGAL Validation Study, marking an important milestone in the company’s clinical efforts to expand ProNephro AKI (NGAL) to the adult population. The
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.